TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05236894

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette Smoking
Description: Smoke preferred brand of cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given lower dose nicotine pouch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given higher dose nicotine pouch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given 3mg nicotine pouch (Aim 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given 3mg nicotine pouch (Aim 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Given 3mg nicotine pouch (Aim 2)
Study: NCT04794205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Beta-Caryophyllene
Description: 5 mg BCP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium Dose Beta-Caryophyllene
Description: 30 mg BCP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Beta-Caryophyllene
Description: 150 mg BCP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo drug.
Study: NCT04829331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restrata
Description: Restrata is a sterile, single use device intended for use in local management of wounds
Study: NCT04701918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous injection through a vein (IV) every 3 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Needle inserted through the skin and into the tumor using CT guidance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Intravenous injection through a vein (IV) every 2 weeks
Study: NCT04911335

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Faringel plus and oral hygiene
Description: The expected frequency of administration of the study product is 2 / day, 10 minutes 'before main meals, for patients without mucositis (grade 1 according to the OAG scale, total score = 8). The frequency of administration will increase to 3 / day for patients with mild or moderate mucositis (grade 2 on the OAG scale, total score 9-18) and up to 4 / day in cases of severe mucositis (grade 3 on the OAG scale, score total 19-24). Each administration will contain 7 ml of oral suspension, to be kept inside the oral cavity for 1-2 minutes and then swallowed slowly.
Study: NCT05950581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Twin-Block Appliance with Clear Plates.
Description: Clear plates technique A group of patients in which participants will be undergo to clear plates treatment will be applied to the upper and lower arch 17 hours daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional Twin-Block appliance
Description: Traditional Twin-Block appliance A group of patients in which participants will undergo to the Traditional Twin-Block appliance Treatment, appliances will be applied to the upper and lower arch 17 hours daily
Study: NCT05919914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with Blood Flow Restriction (BFR)
Description: Wrist extensor exercise (concentric - eccentric) with BFR. BFR involves the reduction of blood flow to working skeletal muscle by applying a flexible cuff to the most proximal portions of a person's arms or legs that results in decreased arterial flow to the exercising muscle and occluded venous return back to the central circulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise without Blood Flow Restriction (BFR)
Description: Wrist extensor exercise (concentric - eccentric)
Study: NCT05109871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KForce Link
Description: Traction (pull-type) dynamometer
Study: NCT05330273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaplacide
Description: Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lumefantrine
Description: Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
Study: NCT04734847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Non-invasive magnetic stimulation of the brain
Study: NCT06408311

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ENC-201-CED hPI
Description: macro-encapsulated human primary islets
Study: NCT05899075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: xylitol wipes
Description: group A will receive xylitol wipes and group B will receive placebo wipes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo wipes
Description: group A will receive xylitol wipes and group B will receive placebo wipes
Study: NCT05026047

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Description: HPV self-sampling in HIV-positive women
Study: NCT04844905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin will be given as tablets of 3 or 6mg. It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken on an empty stomach with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as tablets of 3 or 6mg (identical to Ivermectin in colour, size, shape and packaging). It will be given at 300-400μg/kg/day for 3 days (to the nearest whole tablet) each month for 3 months. It will be taken by mouth with water and without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine will be given as tablets of 320/40mg (adult) and 160/20mg (child) piperaquine/dihydroartemisinin per tablet. Administration of a full course of dihydroartemisinin-piperaquine will be given in accordance with the manufacturer's guidelines once daily for 3 days each month for 3 months according to body weight. Dihydroartemisinin-piperaquine will be taken by mouth with water and without food.
Study: NCT05631522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot reflexology
Description: Warm-Up Phase:~Pre-reflexology foot massage and all-over foot squeeze will be performed for two minutes.~Mini-Reflexology Session:~Specific reflexology will be performed with special attention to two important foot reflex areas that include:~Diaphragm and Solar Plexus Reflex Areas are located in the distance between the upper and middle third of the sole.~The Heart and Lung Reflex Areas are located below the chest of the foot. The heart pumps the oxygen-rich blood around the body
Study: NCT06461247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet Ready-to-eat (VLCD RTE) meals
Description: Participants will be provided with VLCD RTE meals for lunch and dinner for 4 weeks and advised on a healthy ketogenic breakfast. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: Participants will be provided with liquid meal replacement for breakfast, lunch, and dinner for 4 weeks. Additionally, patients are to prepare 1 serving of non-starchy vegetables are to be included for lunch and dinner. Participant will be expected to adhere to VLCD regimen containing 800 calories per day or fewer and keep within 50g net carbohydrates a day.
Study: NCT05353972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007 or placebo
Description: intravenously administered
Study: NCT06483243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
Description: At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: CKD-383, Reference1: Duvie Tab. 0.5mg, Reference2: Jardiance tablets 25 mg, Reference3: GLUCOPHAGE XR TAB. 1000MG
Description: At around 8 a.m., take Test drug or Reference drug 1,2,3(oral) with 200 mL of water at room temperature.
Study: NCT05884424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARO Therapy Robot
Description: Participants allocated to the PARO Therapy Robot group will receive three group robot therapy sessions per week for 12 weeks, in addition to continuing their standard care.~Robot therapy session will last 20 minutes. The sessions will be partially guided, intending to allow participants to interact with the robot seal freely for as long as possible, but redirecting the activity if necessary. The sessions will be conducted in group format, in groups of 4 users, with participants sitting in a circle around a table. The professional conducting the sessions will be a therapist with experience in NPT for people living with dementia, and who has attended the training session on the study intervention protocol.~The sessions will be structured as follows:~1. Welcome and presentation.~2. Main activity with PARO.~3. PARO cleaning.~4. End of session. A total of 13 different sessions are proposed, to be conducted in a cyclical manner (each session 3 times, except sessions 1 and 2).
Study: NCT05583643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin loaded into nano particles in-situ gel adjunctive to scaling and debridement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium
Description: Atorvastatin loaded into in-situ gel adjunctive to scaling and debridement

Intervention type: OTHER
Group type: OTHER
Intervention: Scaling and debridement only
Description: Scaling and debridement only
Study: NCT05578105

Intervention type: OTHER
Intervention: no intervention
Description: No intervention, only observation
Study: NCT05021458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's mobilization
Description: Ten patients will be treated with Gong's mobilization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAG
Description: : Ten patients will be treated with SNAGs
Study: NCT04423627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 0.2 mg/day oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 37.5 mg/day oral tablet
Study: NCT04734847

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (Sham-rTMS)
Description: Device that appears identical to the active rTMS device, but does not produce any magnetic field and does not stimulate the brain.
Study: NCT04423627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05011890

Intervention type: DEVICE
Group type: OTHER
Intervention: Moovcare® use
Description: Moovcare® performs symptom monitoring by automatically delivering ePRO surveys on common symptoms experienced by lung cancer patients. Results are stored in a secure web-based portal for provider review. Providers will manage ePRO responses through a combination of reports graphically displaying responses over time and e-mail alerts about concerning levels or combinations of symptoms.
Study: NCT06431685

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Low Dose Radiotherapy
Description: Whole brain LDRT will be administered at 3 cohorts with increasing dose fractions: Group 1: 4 Gy/2f of one cycle; Group 2: 4 Gy/2f of two cycles (Q3w); Group 3: 4 Gy/2f of three cycles (Q3w). WB-LDRT will be administered in a 4 Gy of 2 fractions over two days, starting from Day 1 in the first cycle (a daily dose of 2 Gy, 4 Gy/2f for one cycle, once per three weeks, at minmum in one cycle and maximum in four cycles in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 30 mg, intrathecal injection, once per three weeks, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: PD-1 inhibitor (Sintilimab, dose as recommended in the instruction manual), intravenous infusion, once per three weeks, 4 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pemetrexed at a dose of 500 mg/m\^2, intravenous infusion, once per three weeks, 4 cycles in total
Study: NCT06204406

Intervention type: OTHER
Intervention: Observational
Description: This is a prospective observational study with observation only and no intervention
Study: NCT06254508

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online program that includes exercise guided by the FITT-VP principle and dietary advice
Description: 1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online program that includes exercise guided by the FITT-VP principle and dietary advice
Description: 1. Week 1: Children received 2 sessions of exercise initiation and 1 session of small group exercise training (45 minutes) with 4\~6 peers.~2. Weeks 2 to 16: 3 small group exercise sessions per week (45 minutes, 4-6 peers) of moderate-to-vigorous physical activity (MVPA). Effective exercise time was assessed by the time subjects reached the heart rate corresponding to the exercise intensity (64-95% of maximal heart rate), as measured by the instantaneous heart rate recorded during each exercise session. The type of exercise was a combination of aerobic, resistance, and flexibility exercises (time ratio 2.5:1:1).~3. Dietary guidance was provided concurrently during the 16-week intervention period: by establishing a WeChat group for caregivers and uploading daily pictures of the day's food to the group, the group's health coaches provided daily targeted dietary guidance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in-clinic nutrition and exercise advice and self-control
Description: Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in-clinic nutrition and exercise advice and self-control
Description: Physicians provide instructions on exercise and nutrition (total daily calorie intake) for the patients to conduct self-control for 16 weeks.
Study: NCT05615805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Description: Ocular Surface Disease Index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Description: Ocular Surface Disease Index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OSDI questionnaire
Description: Ocular Surface Disease Index

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPEEDII questionnaire
Description: Standardized Patient Evaluation of Eye Dryness II questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPEEDII questionnaire
Description: Standardized Patient Evaluation of Eye Dryness II questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPEEDII questionnaire
Description: Standardized Patient Evaluation of Eye Dryness II questionnaire
Study: NCT06278727

Intervention type: DRUG
Intervention: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor
Description: Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.

Intervention type: DRUG
Intervention: angiotensin-converting enzyme inhibitors/angiotensin II receptor blocker/angiotensin receptor-neprilysin inhibitor
Description: Guideline-directed Medical Therapy (GDMT) includes those 4 drugs, and only taking at least 3 drugs could be recognized as GDMT.

Intervention type: OTHER
Intervention: The development of the prediction model
Description: The prediction model of FMR regression would be developed to recognize patients whose FMR would regress due to GDMT, and consequently help determine the treatment.
Study: NCT06337786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital app RB4.1
Description: Standard routine care and the digital app RB4.1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm
Description: Standard routine care
Study: NCT05848882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastodontic Device
Description: Removable device that embraces two dental archs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastodontic Device
Description: Removable device that embraces two dental archs
Study: NCT06509971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: The Order of Drug Administration was: QL1706→ bevacizumab → albumin-binding paclitaxel, and each drug was administered at least 30 minutes apart.~QL1706: 5 mg/kg Q3W. The infusion time was 30 minutes + 5 minutes. No dose adjustment was allowed for QL1706 during treatment, but delayed administration was allowed, with a delay of no more than 4 weeks from the previous dose.~Albumin-binding paclitaxel: 260 mg/m 2 Q3W, IV, for 30 min + 5 min. During treatment, albumin-binding paclitaxel allows for dose adjustments.~Bevacizumab: 15 mg/kg Q3 W, iv. The first infusion should last 90 minutes. If the first infusion was well tolerated, the second infusion could be shortened to 60 minutes. If the patient is also well-tolerated for a 60-minute infusion, then all subsequent infusions can be completed in 30 minutes, no dose adjustment is allowed for bevacizumab.
Study: NCT06034925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: maribavir 400mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: valganciclovir 900mg once daily
Study: NCT05822362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm.
Study: NCT05473689

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Description: Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
Study: NCT06283641

Intervention type: DRUG
Intervention: Liraglutide
Description: Participants will be treated with commercially available Saxenda® according to routine clinical practice at the discretion of the treating physician, following approved label in Taiwan. The decision to initiate treatment with commercially available Saxenda® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Study: NCT05285722

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy form for dental anxiety
Description: Message to Dentist form